The decrease of action potential in myasthenia gravis is due to

summary

Yesterday, I went to my friend Xiao Li's home. I heard that he had another brother, but I didn't get to know him. After I went to his home yesterday, I saw Xiao Li's brother lying in bed all the time, almost unable to take care of himself. Xiao Li told me that his brother had myasthenia gravis. Now it's much better. I'd like to share with you the experience of myasthenia gravis action potential reduction.

The decrease of action potential in myasthenia gravis is due to

Treatment 1: oral or nasal administration, through mucosal induction of immune tolerance, can specifically reduce the antigen of local or systemic immune response. In order to prevent the occurrence of experimental autoimmune myasthenia gravis and inhibit the cellular and humoral immunity against acetylcholine receptor or its peptide, some scholars have given the eel or newborn mice acetylcholine receptor and its subunit A by oral or nasal mucosa before sensitization with acetylcholine receptor. In addition, intranasal administration can avoid the damage of gastric acid and pepsin to the antigen, which requires less antigen dose. A large number of experiments have confirmed that mucosal tolerance alone can only prevent the occurrence of experimental autoimmune myasthenia gravis, and can not effectively block the progress of experimental autoimmune myasthenia gravis.

Treatment 2: immune tolerance induced by dendritic cells, the use of immature dendritic cells, blocking or reducing the immune activation function of dendritic cells, can prevent autoimmune response. The dendritic cells of healthy rats were incubated with transforming growth factor - β 1 and transforming growth factor - γ in vitro, and then injected subcutaneously on the fifth day of experimental autoimmune myasthenia gravis. The results showed that immune tolerance was successfully induced, and the clinical symptoms of experimental autoimmune myasthenia gravis were significantly alleviated. The dendritic cells induced in vitro were the main cause of experimental autoimmune myasthenia gravis Treatment has brought new hope, but its mechanism of action in the treatment of myasthenia gravis is not clear. Moreover, dendritic cells in this state can only prevent the occurrence of experimental autoimmune myasthenia gravis, but can not effectively prevent the progress of the disease.

Treatment 3: Cyclosporin A, which is mainly used for anti rejection of liver, kidney and heart transplantation, can be used with adrenocortical hormone, and can also be used for the treatment of some immune diseases. Adverse reactions: elevated serum creatinine, hypertension, epidemic symptoms, etc.

matters needing attention

This disease needs to pay attention: myasthenia gravis is not a simple disease that can be treated, its recovery needs good nursing and health care in our daily life. If you don't pay attention to the above details in your life, you may make a big mistake.